Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors

ABSTRACT: BACKGROUND: Monoclonal antibodies have become attractive clinical anti-cancer drugs in the last 3 decades due to their targeting specificity and suitable pharmacokinetic properties. Mesothelin is a tumor-associated antigen with limited expression in normal tissues. It is frequently over-ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiao-Yan, Subramanyam, Babu, Sarapa, Nenad, Golfier, Sven, Dinter, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080863/
https://www.ncbi.nlm.nih.gov/pubmed/27853672
http://dx.doi.org/10.2174/2212697X03666160218215744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080863/
https://www.ncbi.nlm.nih.gov/pubmed/27853672
http://dx.doi.org/10.2174/2212697X03666160218215744

Ejemplares similares